39 related articles for article (PubMed ID: 29684854)
1. The potential therapeutic effect of melatonin in oxaliplatin combination therapy against chemoresistant colorectal cancer cells.
Dehghanzad M; Mohammadi M; Nejati M; Pouremamali F; Maroufi NF; Akbarzadeh M; Samadi N; Nouri M
Mol Biol Rep; 2024 Feb; 51(1):348. PubMed ID: 38401018
[TBL] [Abstract][Full Text] [Related]
2. Combinatorial Implications of Nrf2 Inhibitors with FN3K Inhibitor:
Beeraka NM; Zhang J; Zhao D; Liu J; A U C; Vikram Pr H; Shivaprakash P; Bannimath N; Manogaran P; Sinelnikov MY; Bannimath G; Fan R
Curr Pharm Des; 2023; 29(30):2408-2425. PubMed ID: 37861038
[TBL] [Abstract][Full Text] [Related]
3. Small molecules that disrupt RAD54-BLM interaction hamper tumor proliferation in colon cancer chemoresistance models.
Kaur E; Agrawal R; Arun R; Madhavan V; Srivastava V; Kumar D; Rath PP; Kumar N; Vedagopuram S; Pandey N; Priya S; Legembre P; Gourinath S; Bajaj A; Sengupta S
J Clin Invest; 2024 Feb; 134(8):. PubMed ID: 38421735
[TBL] [Abstract][Full Text] [Related]
4. PSMD4 is a novel therapeutic target in chemoresistant colorectal cancer activated by cytoplasmic localization of Nrf2.
Cheng YM; Lin PL; Wu DW; Wang L; Huang CC; Lee H
Oncotarget; 2018 May; 9(41):26342-26352. PubMed ID: 29899863
[TBL] [Abstract][Full Text] [Related]
5.
Situmorang PC; Ilyas S; Syahputra RA; Sari RM; Nugraha AP; Ibrahim A
Front Pharmacol; 2024; 15():1345645. PubMed ID: 38476328
[TBL] [Abstract][Full Text] [Related]
6. Targeted delivery of oxaliplatin via folate-decorated niosomal nanoparticles potentiates resistance reversion of colon cancer cells.
Abdulzehra S; Jafari-Gharabaghlou D; Zarghami N
Heliyon; 2023 Nov; 9(11):e21400. PubMed ID: 37954331
[TBL] [Abstract][Full Text] [Related]
7. Nrf2 inhibition increases sensitivity to chemotherapy of colorectal cancer by promoting ferroptosis and pyroptosis.
Huang Y; Yang W; Yang L; Wang T; Li C; Yu J; Zhang P; Yin Y; Li R; Tao K
Sci Rep; 2023 Sep; 13(1):14359. PubMed ID: 37658132
[TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer.
Vaghari-Tabari M; Hassanpour P; Sadeghsoltani F; Malakoti F; Alemi F; Qujeq D; Asemi Z; Yousefi B
Cell Mol Biol Lett; 2022 Jun; 27(1):49. PubMed ID: 35715750
[TBL] [Abstract][Full Text] [Related]
9. Oxaliplatin induces ferroptosis and oxidative stress in HT29 colorectal cancer cells by inhibiting the Nrf2 signaling pathway.
Liu B; Wang H
Exp Ther Med; 2022 Jun; 23(6):394. PubMed ID: 35495610
[TBL] [Abstract][Full Text] [Related]
10. HNMT Upregulation Induces Cancer Stem Cell Formation and Confers Protection against Oxidative Stress through Interaction with HER2 in Non-Small-Cell Lung Cancer.
Kuo KT; Lin CH; Wang CH; Pikatan NW; Yadav VK; Fong IH; Yeh CT; Lee WH; Huang WC
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163585
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Nrf2 Silencing on Nrf2-PD-L1 Axis to Overcome Oxaliplatin Resistance and Migration in Colon Cancer Cells.
Payandeh Z; Pirpour Tazehkand A; Mansoori B; Khaze V; Asadi M; Baradaran B; Samadi N
Avicenna J Med Biotechnol; 2021; 13(3):116-122. PubMed ID: 34484640
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and Biological Evaluation of New
Apostol TV; Marutescu LG; Draghici C; Socea LI; Olaru OT; Nitulescu GM; Pahontu EM; Saramet G; Enache-Preoteasa C; Barbuceanu SF
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443608
[TBL] [Abstract][Full Text] [Related]
13. A New Oxaliplatin Resistance-Related Gene Signature With Strong Predicting Ability in Colon Cancer Identified by Comprehensive Profiling.
Lin Q; Luo L; Wang H
Front Oncol; 2021; 11():644956. PubMed ID: 34026619
[TBL] [Abstract][Full Text] [Related]
14. Control of Oxidative Stress in Cancer Chemoresistance: Spotlight on Nrf2 Role.
Barrera G; Cucci MA; Grattarola M; Dianzani C; Muzio G; Pizzimenti S
Antioxidants (Basel); 2021 Mar; 10(4):. PubMed ID: 33805928
[TBL] [Abstract][Full Text] [Related]
15. Nuclear Factor Erythroid 2-Related Factor 2 in Regulating Cancer Metabolism.
Smolková K; Mikó E; Kovács T; Leguina-Ruzzi A; Sipos A; Bai P
Antioxid Redox Signal; 2020 Nov; 33(13):966-997. PubMed ID: 31989830
[No Abstract] [Full Text] [Related]
16. Redox-Mediated Mechanism of Chemoresistance in Cancer Cells.
Kim EK; Jang M; Song MJ; Kim D; Kim Y; Jang HH
Antioxidants (Basel); 2019 Oct; 8(10):. PubMed ID: 31658599
[TBL] [Abstract][Full Text] [Related]
17. SMYD2-OE promotes oxaliplatin resistance in colon cancer through MDR1/P-glycoprotein via MEK/ERK/AP1 pathway.
Ren H; Wang Z; Chen Y; Liu Y; Zhang S; Zhang T; Li Y
Onco Targets Ther; 2019; 12():2585-2594. PubMed ID: 31040701
[TBL] [Abstract][Full Text] [Related]
18. The role of Her2-Nrf2 axis in induction of oxaliplatin resistance in colon cancer cells.
Pirpour Tazehkand A; Akbarzadeh M; Velaie K; Sadeghi MR; Samadi N
Biomed Pharmacother; 2018 Jul; 103():755-766. PubMed ID: 29684854
[TBL] [Abstract][Full Text] [Related]
19. The potential impact of trigonelline loaded micelles on Nrf2 suppression to overcome oxaliplatin resistance in colon cancer cells.
Pirpour Tazehkand A; Salehi R; Velaei K; Samadi N
Mol Biol Rep; 2020 Aug; 47(8):5817-5829. PubMed ID: 32661875
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
